DataBreaches.Net

Menu
  • About
  • Breach Notification Laws
  • Privacy Policy
  • Transparency Report
Menu

Perlegen strikes back on privacy

Posted on March 28, 2008October 24, 2024 by Dissent

Healthcare IT News has this story:

Last week, patient privacy advocate Deborah Peel, MD, wrote a letter to Healthcare IT News attacking Perlegen Sciences’ plans to work with an EMR vendor to use patient data for genetics research. In a new letter, Perlegen strikes back at Peel.

To the editor, Healthcare IT News:

We are writing to let you know of the substantial elements of misinformation and misinterpretation that were included in a note you’ve published on 3/21/08, titled “Patient privacy rights advocate attacks plans to mine medical records.”

Perlegen shares with Dr. Peel, the author of the note, the highest regard for maintaining patient privacy. We are actively working to protect that privacy in the context of realizing the substantial clinical benefits we all might expect from the advent of more personalized medicine.

Making personalized medicine a reality relies on the discovery and validation of genetic markers to help predict how individual patients might respond to specific medical treatments. Technology for genetic analysis is no longer the bottleneck, thanks to enormous advances in SNP genotyping and next-generation re-sequencing tools. Rather, it is the lack of clinically appropriate, appropriately consented DNA sample sets that has effectively stymied this effort. Our collaboration for de-identified EMR access is designed to solve this bottleneck, in a way that is absolutely consistent with patient privacy and each individual’s right to self-determination.

To reiterate the point we made in our press release – Perlegen will never have access to the specific identity of any patient, nor will any patient’s DNA ever be collected, much less used, without their prior, written and fully-informed consent. That is the law, and Perlegen is firmly committed to following it in both letter and in spirit.

In fact, we will only have access to de-identified data fields, from which we can sort those case records covering patients from whom we believe a DNA sample might be useful in understanding their variable response to treatments they’ve already received. We then work through our EMR provider, who in turn works with both the medical facilities and physicians that treat those patients.

Before those institutions re-identify any patient, the treating hospital or clinic must receive IRB approval for the study. Only at that point may patients be contacted and informed that preliminary review indicates they might be suitable for the study, and asked if they then consent to further review of their records by their physician.

Read Perlegen’s complete letter on Healthcare IT News

Category: Health Data

Post navigation

← Governor Rendell Signs Executive Order Implementing Information Technology Initiative From Prescription for Pennsylvania
NY to Develop Unified Medical Records →

Now more than ever

"Stand with Ukraine:" above raised hands. The illustration is in blue and yellow, the colors of Ukraine's flag.

Search

Browse by Categories

Recent Posts

  • ConnectWise suspects cyberattack affecting some ScreenConnect customers was state-sponsored
  • Possible ransomware attack disrupts Maine and New Hampshire Covenant Health locations
  • HHS OCR Settles HIPAA Security Rule Investigation of BayCare Health System for $800k and Corrective Action Plan
  • UK: Two NHS trusts hit by cyberattack that exploited Ivanti flaw
  • Update: ALN Medical Management’s Data Breach Total Soars to More than 1.8 Million Patients Affected
  • Russian-linked hackers target UK Defense Ministry while posing as journalists
  • Banks Want SEC to Rescind Cyberattack Disclosure Requirements
  • MathWorks, Creator of MATLAB, Confirms Ransomware Attack
  • Russian hospital programmer gets 14 years for leaking soldier data to Ukraine
  • MSCS board renews contract with PowerSchool while suing them

No, You Can’t Buy a Post or an Interview

This site does not accept sponsored posts or link-back arrangements. Inquiries about either are ignored.

And despite what some trolls may try to claim: DataBreaches has never accepted even one dime to interview or report on anyone. Nor will DataBreaches ever pay anyone for data or to interview them.

Want to Get Our RSS Feed?

Grab it here:

https://databreaches.net/feed/

RSS Recent Posts on PogoWasRight.org

  • Home Pregnancy Test Company Wins Dismissal of Pixel Wiretapping Suit
  • The CCPA emerges as a new legal battleground for web tracking litigation
  • U.S. Spy Agencies Are Getting a One-Stop Shop to Buy Your Most Sensitive Personal Data
  • Period Tracking App Users Win Class Status in Google, Meta Suit
  • AI: the Italian Supervisory Authority fines Luka, the U.S. company behind chatbot “Replika,” 5 Million €
  • D.C. Federal Court Rules Termination of Democrat PCLOB Members Is Unlawful
  • Meta may continue to train AI with user data, German court says

Have a News Tip?

Email: Tips[at]DataBreaches.net

Signal: +1 516-776-7756

Contact Me

Email: info[at]databreaches.net

Mastodon: Infosec.Exchange/@PogoWasRight

Signal: +1 516-776-7756

DMCA Concern: dmca[at]databreaches.net
© 2009 – 2025 DataBreaches.net and DataBreaches LLC. All rights reserved.